Dr. Anthony R. Lanfranco is an interventional pulmonologist and critical care specialist at University of Colorado Medicine. He specializes in numerous procedures integral to the care of patients with pleural mesothelioma, lung cancer, and other pleural and lung diseases, including airway stenting, bronchial stenosis, bronchoscopy, cryotherapy, endoscopic lung volume reduction, and laser bronchoscopy. Education and
Dr. Pettiford is a thoracic surgeon and Section Head for Thoracic Surgery at Ochsner MD Anderson Cancer Center in New Orleans, Louisiana. He has extensive experience in the treatment of pleural mesothelioma and the use of robotic surgery for the treatment of lung cancer, benign lung disease, and esophageal cancer as well as benign lung
For decades, the world has understood asbestos’ role in the development of malignant mesothelioma, lung cancer, and other diseases. Despite this universal knowledge and countless people facing the realities of these painful asbestos-related illnesses, profit-focused companies continue defying protective regulations for asbestos management. In response to one such case, the attorney general of Massachusetts has
Dr. Borghaei is a medical oncologist and specialist in the treatment of lung cancer and pleural mesothelioma at Fox Chase Cancer Center in Philadelphia, Pennsylvania. He holds the positions of Chief of Thoracic Medical Oncology, Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, and the Gloria and Edmund M. Dunn Chair in
Dr. Christian Rolfo is a noted thoracic oncologist and specialist in the treatment of pleural mesothelioma and lung cancer. He holds the title of director of the Division of Medical Oncology at the James Comprehensive Cancer Center at Ohio State University. Education and Career Dr. Rolfo earned his medical degree at the University of Cordoba
A combination of two immunotherapy drugs delivered an “encouraging” response rate in patients with advanced solid tumors, offering new hope for improvement in mesothelioma treatments. The clinical trial revealed a 37.7% objective response to treatment with anti-CTLA-4 human immunoglobulin (Ig) G1 monoclonal antibody CS1002 and the anti-PD-1 humanized recombinant IgG4 monoclonal antibody CS1003, also known
Dr. Corey J. Langer is a medical oncologist and Director of Thoracic Oncology at the Penn Medicine Abramson Cancer Center in Philadelphia, Pennsylvania. He specializes in the treatment of patients diagnosed with lung cancers and pleural mesothelioma and is particularly effective in the use of targeted treatment protocols that combine radiation therapy and immunotherapeutic drugs.
Dr. David Harpole is a thoracic surgeon whose areas of expertise include mesothelioma surgery, lung cancer surgery, surgery for congenital and acquired chest wall abnormalities, and esophageal cancer surgery at the Duke Cancer Institute in Durham, North Carolina. He specializes in minimally invasive thoracic surgery. Education and Career Dr. Harpole earned his medical degree at
Dr. Luis J. Herrera is a thoracic surgeon and the Medical Director of the Rod Taylor Thoracic Care Center at the Orlando Health Cancer Institute. He specializes in the surgical treatment of tumors of the chest, including pleural mesothelioma, lung cancer, and cancers of the esophagus, mediastinum, and chest wall. Education and Career Dr.
Dr. Amin Mirhadi is a radiation oncologist and the Radiation Oncology Director of the Thoracic Oncology Disease Research Group. at Cedars Sinai in Los Angeles, California. He is part of the multidisciplinary mesothelioma and lung cancer team and also provides his expertise in radiation therapy to the treatment of general pulmonology patients, colon cancer patients,